Vimarsana
Biggest News Aggregation in the World

Outcomes From News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Outcomes From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Outcomes From Today - Breaking & Trending Today

Comparative safety of endoscopic vs radiological gastrostomy tube placement: Outcomes from a large, nationwide veterans affairs database - Vimarsana News

Comparative safety of endoscopic vs radiological gastrostomy tube placement: Outcomes from a large, nationwide veterans affairs database

Background: A gastrostomy is a surgical procedure often done when people can’t eat enough food by themselves. The study compared two methods, percutaneous endoscopic gastrostomy (PEG) and interventional radiologist-guided gastrostomy (IRG), using a big national...

Study: Stem Cell Therapy Shows Improvement in QoL for Those With Heart Failure - Vimarsana News

Study: Stem Cell Therapy Shows Improvement in QoL for Those With Heart Failure

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

Clinical trial finds cell therapy improves qu - Vimarsana News

Clinical trial finds cell therapy improves qu

<p>Stem cell-based therapy improved quality of life for patients with advanced&nbsp;<a href="https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142" target="_blank">heart failure</a>,&nbsp;<a href="https://www.mayoclinic.org/" target="_blank">Mayo Clinic</a>&nbsp;researchers and international collaborators discovered in a late-stage multinational clinical trial.</p>

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-&#x3B1; for Ulcerative Colitis - Vimarsana News

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-&#x3B1; for Ulcerative Colitis

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress - Vimarsana News

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual...